Show simple item record

The application and diagnostic utility of immunocytochemistry on direct smears in the diagnosis of pulmonary adenocarcinoma and squamous cell carcinoma

dc.contributor.authorRoh, Michael H.en_US
dc.contributor.authorSchmidt, Lindsayen_US
dc.contributor.authorPlacido, Jeremiahen_US
dc.contributor.authorFarmen, Saraen_US
dc.contributor.authorFields, Kristina L.en_US
dc.contributor.authorCourey, Anthony J.en_US
dc.contributor.authorArenberg, Douglas A.en_US
dc.contributor.authorKnoepp, Stewart M.en_US
dc.date.accessioned2012-11-07T17:04:29Z
dc.date.available2014-01-07T14:51:07Zen_US
dc.date.issued2012-11en_US
dc.identifier.citationRoh, Michael H.; Schmidt, Lindsay; Placido, Jeremiah; Farmen, Sara; Fields, Kristina L.; Courey, Anthony J.; Arenberg, Douglas A.; Knoepp, Stewart M. (2012). "The application and diagnostic utility of immunocytochemistry on direct smears in the diagnosis of pulmonary adenocarcinoma and squamous cell carcinoma." Diagnostic Cytopathology 40(11): 949-955. <http://hdl.handle.net/2027.42/94238>en_US
dc.identifier.issn8755-1039en_US
dc.identifier.issn1097-0339en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/94238
dc.description.abstractThe importance of subclassifying pulmonary nonsmall cell carcinoma (NSCLC) in cytologic material is becoming increasingly paramount. Occasionally, cell blocks traditionally used for ancillary studies are sparsely cellular or acellular. Hence, we investigated the diagnostic utility of immunocytochemistry for Napsin‐A, TTF‐1, and p63 on direct smears of NSCLC. Immunohistochemistry for Napsin‐A was initially tested on a tissue microarray (TMA) composed of pulmonary adenocarcinoma. Subsequently, in 25 cases, immunocytochemistry for Napsin‐A, TTF‐1, and p63 was performed on cytologic direct smears. Smears were prepared from tumor cells scraped from lung resection specimens (n = 10), endobronchial ultrasound‐guided transbronchial fine‐needle aspirates (n = 13), and pelleted cell material from pleural effusions (n = 2). Immunohistochemistry utilizing the TMA revealed Napsin‐A positivity in 73% of pulmonary ADCs. Next, immunocytochemistry on direct cytologic smears demonstrated a Napsin‐A(+)/TTF‐1(+) immunophenotype in 15 of 18 adenocarcinomas; p63 was completely negative (n = 12) or only focally positive (n = 3) in these 15 adenocarcinomas. The remaining three adenocarcinomas were negative for all three markers. All six squamous cell carcinomas were Napsin‐A(−)/TTF‐1(−) and diffusely p63(+). In conclusion, direct smears represent a feasible and robust source of cellular material for immunocytochemical studies to diagnose pulmonary ADC and SQC. Our method allows the cytologist to confirm on site that material for diagnostic immunocytochemistry is present thereby serving as a safeguard in instances where the cell block is of insufficient cellularity. Diagn. Cytopathol. 2012. © 2011 Wiley Periodicals, Inc.en_US
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.subject.otherLung Canceren_US
dc.subject.otherNapsin‐Aen_US
dc.subject.otherTTF‐1en_US
dc.subject.otherP63en_US
dc.subject.otherCytologyen_US
dc.titleThe application and diagnostic utility of immunocytochemistry on direct smears in the diagnosis of pulmonary adenocarcinoma and squamous cell carcinomaen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPathologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pathology, University of Michigan Health System, 1500 E. Medical Center Drive, Ann Arbor, Michigan 48109en_US
dc.contributor.affiliationumDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michiganen_US
dc.identifier.pmid21500373en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/94238/1/21680_ftp.pdf
dc.identifier.doi10.1002/dc.21680en_US
dc.identifier.sourceDiagnostic Cytopathologyen_US
dc.identifier.citedreferenceYang M, Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol 2010; 23: 654 – 661.en_US
dc.identifier.citedreferenceTravis WD, World Health Organization, International Agency for Research on Cancer. International Association for the Study of Lung Cancer, International Academy of Pathology. 2004. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus, and Heart. Lyon: IARC Press; 344 p.en_US
dc.identifier.citedreferenceLadanyi M, Pao W. Lung adenocarcinoma: Guiding EGFR‐targeted therapy and beyond. Mod Pathol 2008; 21 ( Suppl 2 ): S16 – S22.en_US
dc.identifier.citedreferenceTravis WD. Pathology of lung cancer. Clin Chest Med 2002; 23: 65 – 81.en_US
dc.identifier.citedreferenceBesse B, Ropert S, Soria JC. Targeted therapies in lung cancer. Ann Oncol 2007; 18 ( Suppl 9 ): ix135 – ix142.en_US
dc.identifier.citedreferenceHerbst RS. Toxicities of antiangiogenic therapy in non‐small‐cell lung cancer. Clin Lung Cancer 2006; 8 ( Suppl 1 ): S23 – S30.en_US
dc.identifier.citedreferenceJohnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non‐small‐cell lung cancer. J Clin Oncol 2004; 22: 2184 – 2191.en_US
dc.identifier.citedreferenceScagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy‐naive patients with advanced‐stage non‐small‐cell lung cancer. J Clin Oncol 2008; 26: 3543 – 3551.en_US
dc.identifier.citedreferenceMukhopadhyay S, Katzenstein AL. Subclassification of non‐small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF‐1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011; 35: 15 – 25.en_US
dc.identifier.citedreferenceRekhtman N, Brandt SM, Sigel CS, et al. Suitability of thoracic cytology for new therapeutic paradigms in non‐small cell lung carcinoma: High accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol 2011; 6: 451 – 458.en_US
dc.identifier.citedreferenceLau SK, Luthringer DJ, Eisen RN. Thyroid transcription factor‐1: A review. Appl Immunohistochem Mol Morphol 2002; 10: 97 – 102.en_US
dc.identifier.citedreferenceJagirdar J. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. Arch Pathol Laboratory Med 2008; 132: 384 – 396.en_US
dc.identifier.citedreferenceHirano T, Gong Y, Yoshida K, et al. Usefulness of TA02 (napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adenocarcinoma. Lung Cancer 2003; 41: 155 – 162.en_US
dc.identifier.citedreferenceChuman Y, Bergman A, Ueno T, et al. Napsin A, a member of the aspartic protease family, is abundantly expressed in normal lung and kidney tissue and is expressed in lung adenocarcinomas. FEBS Lett 1999; 462: 129 – 134.en_US
dc.identifier.citedreferenceSuzuki A, Shijubo N, Yamada G, et al. Napsin A is useful to distinguish primary lung adenocarcinoma from adenocarcinomas of other organs. Pathol Res Pract 2005; 201: 579 – 586.en_US
dc.identifier.citedreferenceDejmek A, Naucler P, Smedjeback A, et al. Napsin A (TA02) is a useful alternative to thyroid transcription factor‐1 (TTF‐1) for the identification of pulmonary adenocarcinoma cells in pleural effusions. Diagn Cytopathol 2007; 35: 493 – 497.en_US
dc.identifier.citedreferenceStoll LM, Johnson MW, Gabrielson E, et al. The utility of napsin‐A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas. Cancer Cytopathol 2010; 118: 441 – 449.en_US
dc.identifier.citedreferenceTerry J, Leung S, Laskin J, et al. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol 2010; 34: 1805 – 1811.en_US
dc.identifier.citedreferenceOu SH, Zell JA. Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non‐small cell lung cancer histologies. J Thorac Oncol 2009; 4: 1202 – 1211.en_US
dc.identifier.citedreferenceKhayyata S, Yun S, Pasha T, et al. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine‐needle aspiration specimens. Diagn Cytopathol 2009; 37: 178 – 183.en_US
dc.identifier.citedreferenceAbendroth CS, Dabbs DJ. Immunocytochemical staining of unstained versus previously stained cytologic preparations. Acta Cytol 1995; 39: 379 – 386.en_US
dc.identifier.citedreferenceBishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor‐1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol 2010; 41: 20 – 25.en_US
dc.identifier.citedreferenceAu NH, Gown AM, Cheang M, et al. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol 2004; 12: 240 – 247.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.